Safety of twenty-eight-day consumption of \$\Delta G \text{\text{0}}\$ in healthy adults and type 2 diabetes patients

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
28/12/2017		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
10/01/2018	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
27/02/2023	Other			

Plain English summary of protocol

Current plain English summary as of 26/10/2018:

Background and study aims

Emerging evidence shows that calorie restriction and ketogenic diets (low carbohydrate, high fat) improve insulin resistance, weight loss and glucose metabolism. However, both low calorie and ketogenic diets are poorly tolerated. Recently, it became possible to raise blood ketone levels by providing ketones in a drink (ΔG ®) without restricting food intake or carbohydrates. Its consumption for up to five days has been proven to be safe and tolerable. Confirming its consumption for longer periods is safe and well tolerated could translate into a useful new treatment for chronic diseases such as type 2 diabetes and obesity. The aim of this study is to find out whether drinking a ketone ester three times a day for 28 days is safe and well tolerated.

Who can participate?

Healthy volunteers aged 18 - 70 or people with type 2 diabetes aged 18-70. The study is currently only recruiting people with type 2 diabetes and is no longer recruiting healthy volunteers.

What does the study involve?

For healthy volunteers:

Participants drink a 65 ml ketone ester drink three times daily for one month. Participants are asked to keep a dietary log, to take daily glucose and blood ketone pinprick measurements, and to undergo weekly blood tests to assess the safety and tolerability of the ketone ester.

For people with type 2 diabetes:

The study will involve 7 weekly visits either to the Department of Physiology, Anatomy and Genetics (DPAG) or to the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM) over approximately six weeks. Participants will drinking three times daily for 28 days a 65 ml drink containing 25 mg of ΔG ® and 120 calories. It has a bitter taste and participants will get to taste it before enrolling. Participants will also be asked to wear a continuous glucose monitor for 6 weeks. There will be a weekly collection of blood samples and a urine dipstick test.

What are the possible benefits and risks of participating?

In previous safety and tolerance studies, the most reported side effects were mild nausea, abdominal distension and headache. Participants might experience moderate weight loss (less than 5% of total body weight).

Where is the study run from?

University of Oxford and the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (UK)

When is the study starting and how long is it expected to run for? October 2017 to June 2018

Who is funding the study? TdeltaS Ltd (UK)

Who is the main contact? Dr Luis Adrian Soto Mota adrian.soto@dpag.ox.ac.uk

Previous plain English summary:

Background and study aims

Emerging evidence shows that calorie restriction and ketogenic diets (low carbohydrate, high fat) improve insulin resistance, weight loss and glucose metabolism. However, both low calorie and ketogenic diets are poorly tolerated. Recently, it became possible to raise blood ketone levels by providing ketones in a drink (ΔG ®) without restricting food intake or carbohydrates. Its consumption for up to five days has been proven to be safe and tolerable. Confirming its consumption for longer periods is safe and well tolerated could translate into a useful new treatment for chronic diseases such as type 2 diabetes and obesity. The aim of this study is to find out whether drinking a ketone ester three times a day for 28 days is safe and well tolerated.

Who can participate? Healthy volunteers aged 18 - 65

What does the study involve?

Participants drink a 65 ml ketone ester drink three times daily for one month. Participants are asked to keep a dietary log, to take daily glucose and blood ketone pinprick measurements, and to undergo weekly blood tests to assess the safety and tolerability of the ketone ester.

What are the possible benefits and risks of participating?

In previous safety and tolerance studies, the most reported side effects were mild nausea, abdominal distension and headache. Participants might experience moderate weight loss (less than 5% of total body weight).

Where is the study run from?

University of Oxford and the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (UK)

When is the study starting and how long is it expected to run for? October 2017 to June 2018

Who is funding the study? TdeltaS Ltd (UK)

Who is the main contact? Dr Luis Adrian Soto Mota adrian.soto@dpag.ox.ac.uk

Contact information

Type(s)

Public

Contact name

Dr Luis Adrian Soto Mota

ORCID ID

https://orcid.org/0000-0002-9173-7440

Contact details

Department of Physiology, Anatomy and Genetics.
Sherrington Building
Parks Road
Oxford
United Kingdom
OX1 3PT
+44 (0)1865 272 500
adrian.soto@dpag.ox.ac.uk

Additional identifiers

Protocol serial number

DELTAGHP2018

Study information

Scientific Title

Safety of twenty-eight-day consumption of ΔG ® in healthy adults and type 2 diabetes patients: a non-randomised study

Study objectives

Consuming 25 mg of a ketone ester three times a day during 28 days will be safe and well tolerated by healthy adults.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South Central - Oxford B Research Ethics Committee, 07/03/2018, REC ref: 18/SC/0064

Study design

Prospective non-randomised open-label single-group study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Consumption of a ketone ester

Interventions

Consumption of a drink containing 25 mg of a ketone ester three times a day for 28 days. Participants will be asked to keep a dietary log, to take daily glucose and blood ketone pinprick measurements and to undergo weekly blood tests.

Intervention Type

Supplement

Primary outcome(s)

Measured at baseline and weekly after the start of the intervention until the end of participation:

- 1. Tolerability, measured with the reported frequency and severity of adverse effects using open questions: "Have you experienced any unpleasant symptoms in the last week?","How frequently?" and all symptoms graded as "mild", "moderate" or "severe"
- 2. Safety, assessed with blood samples, particularly levels of beta-hydroxybutyrate and pH

Key secondary outcome(s))

Measured at baseline and weekly after the start of the intervention until the end of participation:

- 1. Weight and body composition measured with electric bioimpedance
- 2. Insulin sensitivity assessed with the HOMA-IR score

Completion date

30/06/2020

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 26/10/2018:

This study is currently only recruiting people with type 2 diabetes.

People with type 2 diabetes:

- 1. Type2 diabetes patients who don't use or need insulin and who have had the same treatment for the last 6 months. Confirmation of eligibility from your GP will be requested.
- 2. Fluent in English
- 3. Males, or females using hormonal birth control if sexually active
- 4. Aged 18-70

Healthy volunteers (not currently open to recruitment):

- 1. Participants must be fluent in English, have no communication impairments and should be willing and able to give informed consent for participation in the trial
- 2. Aged 18 70 (inclusive)
- 3. With no known medical diagnosis

4. Have had no course of medication, whether prescribed or over-the-counter, in the four weeks before the first trial dose and no individual doses in the final two weeks other than over the counter analgesics, vitamins and mineral supplements or, for females, oral contraceptives
5. Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner mechanical or pharmacological contraception during the trial and for 3 months thereafter
6. In the Investigator's opinion, is able and willing to comply with all trial requirements
7. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial

Previous participant inclusion criteria:

- 1. Participants must be fluent in English, have no communication impairments and should be willing and able to give informed consent for participation in the trial
- 2. Aged 18 70 (inclusive)
- 3. With no known medical diagnosis
- 4. Have had no course of medication, whether prescribed or over-the-counter, in the four weeks before the first trial dose and no individual doses in the final two weeks other than over the counter analgesics, vitamins and mineral supplements or, for females, oral contraceptives 5. Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner mechanical or pharmacological contraception during the trial and for 3 months thereafter 6. In the Investigator's opinion, is able and willing to comply with all trial requirements 7. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

70 years

Sex

All

Total final enrolment

21

Key exclusion criteria

- 1. Female participant who is pregnant, lactating or planning pregnancy during the trial
- 2. Significant renal or hepatic impairment
- 3. Scheduled elective procedures requiring general anaesthesia during the trial
- 4. Any other significant disease or disorder which, in the opinion of the investigator, may either

put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial 5. Participants who have participated in another research trial involving an investigational product in the past 12 weeks

Date of first enrolment 01/02/2018

Date of final enrolment 30/04/2020

Locations

Countries of recruitment United Kingdom

England

Study participating centre
University of Oxford
Department of Physiology, Anatomy and Genetics
Sherrington Building
Parks Road
Oxford
United Kingdom
OX1 3PT

Study participating centre
Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism
University Hospital
Clifford Bridge Road
Coventry
United Kingdom
CV2 2DX

Sponsor information

Organisation

TdeltaS Ltd

Funder(s)

Funder type

Industry

Funder Name

TdeltaS Ltd

Results and Publications

Individual participant data (IPD) sharing plan

Access will be granted to authorised representatives from the Sponsor, host institution and the regulatory authorities to permit trial-related monitoring, audits and inspections. To request it, contact Professor Kieran Clarke (info@tdeltas.com).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/05/2021	27/02/2023	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes